

Web Appendix

FIGURE LEGENDS

Figure A1. Primary Platelet Reactivity Outcome: Difference in platelet reactivity units (PRU) after treatment between TAPT vs. DAPT stratified by baseline acute coronary syndrome (ACS) status

Figure A2. Primary Platelet Reactivity Outcome: Difference in platelet reactivity units (PRU) after treatment between TAPT vs. DAPT stratified by baseline clopidogrel resistance status

Figure A3. Secondary Platelet Reactivity Outcome: Difference in percent platelet inhibition after treatment between TAPT vs. DAPT stratified by baseline acute coronary syndrome (ACS) status

Figure A4. Secondary Platelet Reactivity Outcome: Difference in percent platelet inhibition after treatment between TAPT vs. DAPT stratified by baseline clopidogrel resistance status

Figure A5. Secondary Platelet Reactivity Outcome: Risk of High On-treatment Platelet Reactivity (HTPR) after treatment between TAPT vs. DAPT stratified by baseline acute coronary syndrome (ACS) status

Figure A6. Secondary Platelet Reactivity Outcome: Risk of High On-treatment Platelet Reactivity (HTPR) after treatment between TAPT vs. DAPT stratified by baseline clopidogrel resistance status

Figure A1. Primary Platelet Reactivity Outcome: Difference in platelet reactivity units (PRU) after treatment between TAPT vs. DAPT stratified by baseline acute coronary syndrome (ACS) status




Figure A2. Primary Platelet Reactivity Outcome: Difference in platelet reactivity units (PRU) after treatment between TAPT vs. DAPT stratified by baseline clopidogrel resistance status




Figure A3. Secondary Platelet Reactivity Outcome: Difference in percent platelet inhibition after treatment between TAPT vs. DAPT stratified by baseline acute coronary syndrome (ACS) status




Figure A4. Secondary Platelet Reactivity Outcome: Difference in percent platelet inhibition after treatment between TAPT vs. DAPT stratified by baseline clopidogrel resistance status




Figure A5. Secondary Platelet Reactivity Outcome: Risk of High On-treatment Platelet Reactivity (HTPR) after treatment between TAPT vs. DAPT stratified by baseline acute coronary syndrome (ACS) status




Figure A6. Secondary Platelet Reactivity Outcome: Risk of High On-treatment Platelet Reactivity (HTPR) after treatment between TAPT vs. DAPT stratified by baseline clopidogrel resistance status

